AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2080949 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium (9 mmol Calcium-Sandoz)
Number of subjects: 25
Study 2080949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 396055 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 3 x 20 mg/kg
Number of subjects: 51
Study 396055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 396055 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 1 x 20 mg/kg and 2 x 20 mg/kg
Number of subjects: 51
Study 31226123 — intervention group
Group type: EXPERIMENTAL
Intervention: Family planning voucher
Number of subjects: 173
Study 31226123 — intervention group
Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 173
Study 28001151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g per day of DSG for 14 days
Number of subjects: 203
Study 28001151 — intervention group
Group type: COMPARATOR
Intervention: 5 g per day of DSG for 30 days
Number of subjects: 203
Study 28001151 — intervention group
Group type: COMPARATOR
Intervention: 5 g per day of placebo for 30 days
Number of subjects: 203
Study 28001151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g per day of DSG for both studies
Number of subjects: 203
Study 25648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones supplementation (33 g in the form of biscuits containing approximately 54 mg isoflavones for 8 weeks)
Number of subjects: 61
Study 25648211 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones supplementation
Number of subjects: 61
Study 23206316 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (Group A)
Number of subjects: 86
Study 23206316 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation plus breathing exercises (Group B)
Number of subjects: 86
Study 23206316 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed mobilisation plus breathing exercises (Group C)
Number of subjects: 86
Study 21112195 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% mouth rinse
Number of subjects: 37
Study 21112195 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% gel
Number of subjects: 37
Study 21112195 — intervention group
Group type: COMPARATOR
Intervention: Thy-Car mixture (control)
Number of subjects: 37
Study 19679843 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin-receptor antagonists (ETRAs)
Number of subjects: 867
Study 17885991 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium difficulty details mixed with hard details
Number of subjects: 0
Study 17885991 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium difficulty details presented in blocked format preceded by a block of hard details
Number of subjects: 0
Study 17885991 — intervention group
Group type: EXPERIMENTAL
Intervention: Informing participants of the relative difficulty of the upcoming block of details
Number of subjects: 0
Study 15329425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg) weekly for six months
Number of subjects: 387
Study 15329425 — intervention group
Group type: COMPARATOR
Intervention: Placebo weekly for six months
Number of subjects: 387
Study 11158796 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 108
Study 11158796 — intervention group
Group type: COMPARATOR
Intervention: Unoprostone 0.12% twice daily
Number of subjects: 108
Study 9500800 — intervention group
Group type: EXPERIMENTAL
Intervention: Information (N=61)
Number of subjects: 115
Study 9500800 — intervention group
Group type: COMPARATOR
Intervention: No information (N=54)
Number of subjects: 115
Study 7826846 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) only in 50 patients
Number of subjects: 139
Study 7826846 — intervention group
Group type: EXPERIMENTAL
Intervention: VP‐16 and other drugs with leukemogenic effect in 17 patients
Number of subjects: 139
Study 7826846 — intervention group
Group type: EXPERIMENTAL
Intervention: Only drugs with leukemogenic effect in 6 patients
Number of subjects: 139
Study 7826846 — intervention group
Group type: EXPERIMENTAL
Intervention: Other drugs in 35 patients
Number of subjects: 139
Study 7826846 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery only in 31 patients
Number of subjects: 139
Study 30595329 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg/day
Number of subjects: 116
Study 30595329 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg/day
Number of subjects: 116
Study 30595329 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 116
Study 30595329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30595329 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (all doses combined)
Number of subjects: 116
Study 29917338 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 74
Study 29917338 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 74
Study 24056161 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct lateral approach
Number of subjects: 35
Study 24056161 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 35
Study 24056161 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 35
Study 24056161 — intervention group
Group type: COMPARATOR
Intervention: All approaches
Number of subjects: 35
Study 22397653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg twice daily
Number of subjects: 162
Study 22397653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg twice daily
Number of subjects: 162
Study 22397653 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (both doses)
Number of subjects: 162
Study 20064692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1 mg ml(‐1)
Number of subjects: 18
Study 20064692 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 18
Study 19368505 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7) given 3 months after transplantation
Number of subjects: 158
Study 19368505 — intervention group
Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7) given 9 months after transplantation
Number of subjects: 158
Study 16418785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 5-10 mg/day
Number of subjects: 6186
Study 16418785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 6186
Study 16418785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 6186
Study 15288321 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (4.0 g total over 4 weeks, 1000 mg weekly)
Number of subjects: 125
Study 15288321 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 28 days)
Number of subjects: 125
Study 11340962 — intervention group
Group type: EXPERIMENTAL
Intervention: Research methods and ethical standards in studies involving persons with mental retardation
Number of subjects: 0
Study 11340962 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent and surrogate decision-making
Number of subjects: 0
Study 9240875 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet tritiated imipramine (3H‐IMI) binding sites in coeliac disease patients
Number of subjects: 20
Study 9240875 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 8482456 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg three times a day, n = 57)
Number of subjects: 118
Study 8482456 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (up to maximum tolerated dose, n = 61)
Number of subjects: 118
Study 8482456 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 118
Study 8482456 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 118
Study 2446058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg doses twice daily)
Number of subjects: 124
Study 2446058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + Atenolol (100 mg/day)
Number of subjects: 124
Study 2446058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin + Hydrochlorothiazide (50 mg/day) + Amiloride (5 mg/day)
Number of subjects: 124
Study 2446058 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 124
Study 29304837 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiBIRTH intervention
Number of subjects: 0
Study 27865174 — intervention group
Group type: EXPERIMENTAL
Intervention: cART+48 weeks of MVC (LT-MVC)
Number of subjects: 29
Study 27865174 — intervention group
Group type: EXPERIMENTAL
Intervention: cART+8 weeks of MVC (ST-MVC)
Number of subjects: 29
Study 27865174 — intervention group
Group type: COMPARATOR
Intervention: cART-only (control group)
Number of subjects: 29
Study 24252173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (gradual sleep extension by advancing bedtimes in the evening and receiving sleep hygiene advice)
Number of subjects: 55
Study 24252173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 55
Study 22156663 — intervention group
Group type: EXPERIMENTAL
Intervention: Admira Flow
Number of subjects: 35
Study 22156663 — intervention group
Group type: EXPERIMENTAL
Intervention: Grandio Flow
Number of subjects: 35
Study 22156663 — intervention group
Group type: COMPARATOR
Intervention: Fissurit F
Number of subjects: 35
Study 20728065 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined abbreviated progressive relaxation technique (APRT) and guided imagery (GI) intervention
Number of subjects: 19
Study 20728065 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study 18278830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 748
Study 18278830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 748
Study 18278830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 748
Study 18278830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748
Study 18278830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 748
Study 15963092 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg once daily
Number of subjects: 371
Study 15963092 — intervention group
Group type: COMPARATOR
Intervention: Interferon‐alfa plus cytarabine
Number of subjects: 371
Study 12906966 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v.+s.c. enoxaparin treatment
Number of subjects: 25
Study 12906966 — intervention group
Group type: COMPARATOR
Intervention: s.c. alone enoxaparin treatment
Number of subjects: 25
Study 10470389 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil (Group SR)
Number of subjects: 40
Study 10470389 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl-etomidate (Group FE)
Number of subjects: 40
Study 8735046 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 16
Study 8735046 — intervention group
Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 16
Study 1817627 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental spinal anaesthesia using a 32-gauge catheter with 0.5% plain bupivacaine
Number of subjects: 43
Study 1817627 — intervention group
Group type: COMPARATOR
Intervention: Extradural anaesthesia with pH-adjusted 2% lignocaine with 1/200,000 adrenaline
Number of subjects: 43
Study 7066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg ml‐1 administered in sitting position
Number of subjects: 40
Study 7066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 5 mg ml‐1 administered in horizontal position
Number of subjects: 40
Study 7066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg ml‐1 in horizontal posture
Number of subjects: 40
Study 7066128 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 5 mg ml‐1 in horizontal posture
Number of subjects: 40
Study 31625497 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the metacognitive training (MCT) program, 18 sessions, 60 min per session, over 14 weeks
Number of subjects: 59
Study 31625497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 59
Study 30260724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% levobupivacaine applied at incision sites + 10 mL 0.5% levobupivacaine injected intraperitoneally and at trocar sites
Number of subjects: 120
Study 30260724 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% ropivacaine at incision sites + 10 mL 0.5% ropivacaine injected intraperitoneally and at trocar sites
Number of subjects: 120
Study 30260724 — intervention group
Group type: COMPARATOR
Intervention: No peritoneal or local administration of local anesthetics (Control Group 1)
Number of subjects: 120
Study 27165179 — intervention group
Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 879
Study 27165179 — intervention group
Group type: COMPARATOR
Intervention: PBO+MTX
Number of subjects: 879
Study 25331992 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention for indicated prevention of depression
Number of subjects: 173
Study 25331992 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 173
Study 25331992 — intervention group
Group type: EXPERIMENTAL
Intervention: Good complier caregivers
Number of subjects: 173
Study 23291916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (settings: 6 W, 60 mJ/pulse, and 100 Hz)
Number of subjects: 0
Study 23291916 — intervention group
Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 0
Study 23291916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study 22449648 — intervention group
Group type: EXPERIMENTAL
Intervention: Transformational leadership
Number of subjects: 140
Study 22449648 — intervention group
Group type: COMPARATOR
Intervention: Leader-member exchange
Number of subjects: 140
Study 22449648 — intervention group
Group type: EXPERIMENTAL
Intervention: EBPI (evidence-based practice implementation)
Number of subjects: 140
Study 22449648 — intervention group
Group type: COMPARATOR
Intervention: SAU (services as usual)
Number of subjects: 140
Study 19541954 — intervention group
Group type: EXPERIMENTAL
Intervention: XBD173
Number of subjects: 0
Study 19541954 — intervention group
Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0
Study 17560989 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy for cutaneous melanoma
Number of subjects: 0
Study 15729204 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy approaches including antibodies, peptides, or dendritic cell vaccines
Number of subjects: 0
Study 11469160 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate debriefing (< 10 hr)
Number of subjects: 77
Study 11469160 — intervention group
Group type: COMPARATOR
Intervention: Delayed debriefing (> 48 hr)
Number of subjects: 77
Study 9211625 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg s.c., bid and 1.5 mg/kg s.c. daily)
Number of subjects: 17
Study 9211625 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 17
Study 8433421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy (including enteric-coated aspirin and plain aspirin)
Number of subjects: 444
Study 8433421 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 444
Study 8433421 — intervention group
Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 444
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 135
Study 3310094 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 135
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo (SE) pulse sequence
Number of subjects: 135
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion-recovery (IR) pulse sequence
Number of subjects: 135
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted pulse sequences (TE 60 msec)
Number of subjects: 135
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: T2-weighted pulse sequences (TE 120 msec)
Number of subjects: 135
Study 3310094 — intervention group
Group type: EXPERIMENTAL
Intervention: Single T1-weighted (10-minute) pulse sequence
Number of subjects: 135
Study 31664303 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (200 mg)
Number of subjects: 50
Study 31664303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26731483 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg
Number of subjects: 85
Study 26731483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 26731483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tumor load subgroup (n=64)
Number of subjects: 85
Study 26731483 — intervention group
Group type: EXPERIMENTAL
Intervention: High tumor load subgroup (n=21)
Number of subjects: 85
Study 25667217 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 4% (0.2 mL)
Number of subjects: 17
Study 25667217 — intervention group
Group type: COMPARATOR
Intervention: Decongestant only
Number of subjects: 17
Study 24967526 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence Estimator (AE) tool
Number of subjects: 388
Study 24967526 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Adherence Work-up (DRAW) tool
Number of subjects: 388
Study 21074608 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐epicatechin (1.5mg/kg bw)
Number of subjects: 0
Study 21074608 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)‐catechin (1.5mg/kg bw)
Number of subjects: 0
Study 21074608 — intervention group
Group type: EXPERIMENTAL
Intervention: +‐catechin (1.5mg/kg bw)
Number of subjects: 0
Study 21074608 — intervention group
Group type: EXPERIMENTAL
Intervention: +‐epicatechin (1.5mg/kg bw)
Number of subjects: 0
Study 19523049 — intervention group
Group type: EXPERIMENTAL
Intervention: early-NIPPV
Number of subjects: 76
Study 19523049 — intervention group
Group type: COMPARATOR
Intervention: early-CPAP
Number of subjects: 76
Study 18162724 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 118
Study 18162724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 15554461 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapeutic ego strengthening (HES) intervention pre- and postoperatively
Number of subjects: 50
Study 15554461 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 50
Study 11681004 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (combination therapy with mitomycin C, 5-fluorouracil, and nonspecific immunomodulators such as PSK and OK-432)
Number of subjects: 0
Study 11681004 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical modulators (low-dose FP and S 1)
Number of subjects: 0
Study 11681004 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study 9716216 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 0
Study 7664193 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training (weekly group sessions of 60 min for 1 year)
Number of subjects: 0
Study 7664193 — intervention group
Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 0
Study 2718782 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-25-OHD (1200 mg/day of calcium as calcium carbonate and 40 micrograms/day of 25-OHD)
Number of subjects: 39
Study 2718782 — intervention group
Group type: COMPARATOR
Intervention: Calcium-placebo (1200 mg/day of calcium plus placebo)
Number of subjects: 39
Study 2718782 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-25-OHD and Calcium-placebo
Number of subjects: 39
Study 1097097 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin (25 mg/m given intravenously) + Methotrexate (25 mg/m/dose given orally twice weekly)
Number of subjects: 63
Study 1097097 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (25 mg/m/dose given orally twice weekly)
Number of subjects: 63
Study 30683167 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care using SpiPas and usual care
Number of subjects: 46
Study 30683167 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 28619228 — intervention group
Group type: EXPERIMENTAL
Intervention: Lite intervention (8 community health club sessions)
Number of subjects: 8734
Study 28619228 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic intervention (20 community health club sessions)
Number of subjects: 8734
Study 28619228 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8734
Study 25817614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebrobasilar ectasia (VBE) present in 200 (7.6%) patients
Number of subjects: 2621
Study 23702094 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (DHA and EPA)
Number of subjects: 0
Study 23702094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21375762 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg plus amiloride 2.5 mg
Number of subjects: 1250
Study 21375762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250
Study 19713967 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HHQ-reduced coffee (300 mg chlorogenic acids per 184 ml of coffee)
Number of subjects: 21
Study 19713967 — intervention group
Group type: COMPARATOR
Intervention: Placebo HHQ-reduced coffee (0 mg chlorogenic acids per 184 ml of coffee)
Number of subjects: 21
Study 19713967 — intervention group
Group type: EXPERIMENTAL
Intervention: Active HHQ-reduced coffee
Number of subjects: 21
Study 19713967 — intervention group
Group type: COMPARATOR
Intervention: Placebo HHQ-reduced coffee
Number of subjects: 21
Study 17597089 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC rinse with unfractionated heparin (UFH)
Number of subjects: 10